Neurimmune inks US-$760 deal with AstraZeneca
Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
Santhera finds Chinese marketing partner for vamorolone
/in News/by Thomas GabrielczykSwiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
DNA Script bags US$200m financing
/in News/by Thomas GabrielczykModerna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Sound Bioventures Fund I AB closes at 110m
/in News/by Thomas GabrielczykNovo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put 110m in the first fund of Sound Bioventures AB.
Omicron variant more harmless than Delta
/in News/by Thomas GabrielczykThe new year begins with good news.
Season Greetings
/in News/by Thomas GabrielczykMerry Christmas and a Happy New Year!
Novo Holdings invests 86m in 21st.BIO
/in News/by Thomas GabrielczykNovo Holdings is set to invest 86m in 21st.BIO A/S a new Danish bioindustrial scale-up company to boost the production of proteins.
Novartis AG snags Gyroscope for US$1.5bn
/in News/by Thomas GabrielczykOcular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.
NorthSea Therapeutics completes US$80m Series C financing
/in News/by Thomas GabrielczykDutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.
Depixus raises 30.6m in Series A financing
/in News/by Thomas GabrielczykFrench-British magnetic trap specialist Depixus has raised 30,6m to develop a commercial instrument based on the companys MAGNA technology.